159 related articles for article (PubMed ID: 30784932)
1. The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB.
Al-Gayyar MMH; Bagalagel A; Noor AO; Almasri DM; Diri R
Biomed Pharmacother; 2019 Apr; 112():108653. PubMed ID: 30784932
[TBL] [Abstract][Full Text] [Related]
2. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
3. Activation of AKT pathway by Nrf2/PDGFA feedback loop contributes to HCC progression.
Liu D; Zhang Y; Wei Y; Liu G; Liu Y; Gao Q; Zou L; Zeng W; Zhang N
Oncotarget; 2016 Oct; 7(40):65389-65402. PubMed ID: 27588483
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma.
Price JA; Kovach SJ; Johnson T; Koniaris LG; Cahill PA; Sitzmann JV; McKillop IH
Hepatology; 2002 Nov; 36(5):1089-97. PubMed ID: 12395318
[TBL] [Abstract][Full Text] [Related]
5. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats.
R Ebrahim A; El-Mesery M; El-Karef A; Eissa LA
Can J Physiol Pharmacol; 2018 Dec; 96(12):1218-1225. PubMed ID: 30205014
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
9. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
11. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
12. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.
Chang TS; Chen CL; Wu YC; Liu JJ; Kuo YC; Lee KF; Lin SY; Lin SE; Tung SY; Kuo LM; Tsai YH; Huang YH
PLoS One; 2016; 11(2):e0149897. PubMed ID: 26919045
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth.
Park SY; Lee KB; Lee MJ; Bae SC; Jang JJ
J Cell Physiol; 2012 Mar; 227(3):899-908. PubMed ID: 21503886
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression.
Ma-On C; Sanpavat A; Whongsiri P; Suwannasin S; Hirankarn N; Tangkijvanich P; Boonla C
Med Oncol; 2017 Apr; 34(4):57. PubMed ID: 28281193
[TBL] [Abstract][Full Text] [Related]
16. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
17. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
[TBL] [Abstract][Full Text] [Related]
19. Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways.
Elsherbiny NM; Eisa NH; El-Sherbiny M; Said E
Environ Toxicol Pharmacol; 2020 Nov; 80():103494. PubMed ID: 32942000
[TBL] [Abstract][Full Text] [Related]
20. Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma.
Al-Gayyar MM; Abbas A; Hamdan AM
Biol Chem; 2016 Mar; 397(3):257-67. PubMed ID: 26733159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
